Smooth muscle cell (SMC) differentiation is an essential component of vascular development and these cells perform biosynthetic, proliferative and contractile roles in the vessel wall. SMC are not terminally differentiated and possess the ability to modulate their phenotype in response to changing local environmental cues. The focus of this review is to provide an overview of the current state of knowledge of molecular mechanisms involved in controlling phenotypic switching of SMC with particular focus on examination of processes that contribute to the repression of SMC marker genes.
models of graft arteriosclerosis, may be derived from various alternative sources including circulating bone marrow derived stem cells (82, 86) , and/or resident Sca1+ adventitial stem cells (29) [reviewed in Hoofnagle et al (27) ]. There is also evidence suggesting that SMC or SMC-like cells within an injured blood vessel in animal models, or human atherosclerotic lesion may be derived from a variety of sources including medial SMC (91) , trans-differentiation of endothelial cells (12) and adventitial fibroblasts (46, 83) [reviewed in Sartore et al (81) ]. However, irrespective of the source of SMC, the principal of local environmental cues impacting the patterns of gene expression and behavior of these cells apply.
Expression of many SMC marker genes has been shown to be dependent on multiple CArG
[CC(A/T) 6 GG] elements and their binding factor, serum response factor (SRF) (48, 55, 59, 63) . SRF has been reported to activate multiple SM genes by recruiting several other cofactors [this topic is elegantly reviewed by Miano et al (64) . Indeed until now, no master genes have been found to play a role comparable to that of MyoD (15) in skeletal muscle development, although several genes have been found to have some role in this process. One of the most significant advances in this field of SMC differentiation was the identification of myocardin, which was discovered as a co-activator of SRF-dependent transcription exclusively expressed in cardiac and SMC lineages (8, 14, 95, 103) .
Myocardin activates smooth and cardiac muscle promoters by its interaction with SRF. Of significance, myocardin has been shown to selectively induce expression of all CArG-dependent SMC marker genes tested to date including smooth muscle -actin (SM -actin), smooth muscle-myosin heavy chain (SM-MHC), SM22 , calponin and telokin but not c-fos (102) . Studies of telokin are of particular interest in that this gene, unlike all other CArG containing SMC marker genes characterized to data, has a single rather than multiple CArG elements, as is the case for early response genes such as c-fos (25). Indeed, a series of highly innovative studies by Herring and co-workers have defined unique Myocardin-induced activation of SMC genes appears to depend on the interaction between myocardin and SRF rather than on direct DNA binding, such that an understanding of mechanisms that control SRF binding to CArG elements is critical to fully understanding SMC-selective gene expression. Mouse embryos homozygous for a myocardin loss-of-function mutation died by embryonic day (E) 10.5 and showed failed development of SMC, whereas cardiac development appeared to be normal (50). However, autonomous myocardin is not absolutely required for SMC development, in that we, in collaboration with E. Olson and co-workers recently showed that homozygous myocardin-null
ES cells can differentiate into SMC in vitro within an ES cells-embryoid body model of SMC differentiation in vivo as well as in vivo in the context of chimeric knockout mice produced by injection of lineage tagged myocardin -/-ES cells into wildtype blastocysts (71). In brief, myocardin null ES
cells populated both vascular and non-vascular SMC tissues, and stained with antibodies to the SMC marker genes such as SM -actin and SM-MHC. However, it remains to be determined whether myocardin null ES cells exhibit more subtle defects in SMC differentiation and/or function. In addition, although it is likely that the myocardin related transcription factors, MRTF-A (MKL1) and/or MRTF-B (MKL2) (96) , can compensate for loss of myocardin within chimeric knockout mice, at present there is no direct experimental evidence for this. Indeed, there is emerging evidence that different SMC subtypes may exhibit differential dependence on myocardin and/or MRTFs. For example, the Parmacek and Olson labs recently independently showed that MRTF-B is required for differentiation of SMC in neural crest derived SMC but dispensable for SMC development in other tissues (47, 68). As such, at present, there is ambiguity as to unique versus overlapping functions of myocardin versus MRTFs in SMC development. However, myocardin is exclusively expressed in SMC and cardiac myocytes (14) , Although SMC can undergo quite diverse forms of phenotypic switching, a hallmark feature of SMC phenotypic switching during vascular injury-repair or in many SMC related disease states is down-regulation of expression of SMC specific/selective marker genes such as SM -actin, SM-MHC, SM22 , and desmin. As such, there has been interest in identifying molecular mechanisms that repress SMC marker gene expression. As will be summarized in the next section there is evidence that SMC phenotypic switching results not only from loss of positive differentiation signals and pathways, but also by induction of multiple complementary active repressor pathways that suppress SMC gene expression. This review will focus on summarizing recent advances in our understanding of the molecular mechanisms that control SMC phenotypic switching with a particular emphasis on consideration of mechanisms that alter expression of the large repertoire of SMC marker genes whose expression is dependent on CArG elements in their promoter-enhancers and binding of SRF and SRF co-activators such as myocardin and the MRTFs. For a much more comprehensive review of CArG-SRF transcription, please see the elegant recent review by Miano (62) .
II.
Phenotypic switching is actively regulated and is not simply due to loss of positive 
III.
Repressive pathways implicated in SMC phenotypic switching in vivo.
To begin to define which of the wide plethora of altered environmental cues associated with vascular injury contribute to phenotypic switching of vascular SMC, we asked the following questions. promoters to drive expression of -galactosidase in a manner that parallels the expression of the endogenous gene throughout embryonic development and in adult mice (37, 49, 55, 56). We carried out a series of vascular injury experiment in these transgenic mice, and showed nearly complete loss of expression of all three transgenes following vascular injury, thus demonstrating for first time that SMC phenotypic modulation in vivo was mediated at least in part by transcriptional repression (74) . We subsequently completed a series of studies using site directed mutagenesis and transgenic mouse models to define cis-elements required for injury-induced repression of SM22 and SM -actin in vivo downregulation in transgenic mice, although this substitution had no effect on smooth muscle specific expression during normal development and maturation in transgenic mice (23). We also demonstrated that expression of myocardin mRNA was significantly decreased within 3 days following injury compared to the uninjured control, but it returned to control level by 7 days after rat carotid artery injury during which time there was re-induction of SMC gene expression in medial SMC in this injury model (23). We hypothesized that the reduction in myocardin expression resulted in loss of SRF binding to the wildtype degenerate SM -actin CArG elements (and silencing), whereas the SRE substituted mutant SM -actin promoter bound SRF despite reductions in myocardin levels. Consistent with this hypothesis, we showed that the wild type SM -actin promoter exhibited a greater myocardin dependency than the SRE substituted promoter. Moreover, myocardin increased SRF association with the CArG-containing region of the SM -actin promoter but not of the c-fos promoter in intact chromatin (23, 61). Taken together, these observations indicate that although CArG degeneracy is not a critical determinant of SMC specific expression of SMC marker genes, it is required for repression of expression of these genes in response to vascular injury. 
IV. PDGF-BB represses SMC gene expression through multiple complementary repressor pathways.
Although there is no direct evidence that PDGF-BB is required for phenotypic switching of vascular SMC in vivo, there is certainly circumstantial evidence for its involvement (See Section II).
Indeed, PDGF-BB is the only factor described to date that can induce rather profound suppression of SMC marker genes (3, 10, 11, 92) . The aim of this section will be to summarize studies that have including SM22 , and SM -actin. These studies were subsequently extended by P. Herring and co-workers who presented evidence that ERK dependent phosphorylation of the SRF co-activator Elk-1 is likely to modulate not only selective silencing of CArG dependent SMC genes but also activation of growth regulatory genes (106, 107) . That is, it is well established that phosphorylation of Elk-1 increases its binding to the c-fos promoter and activation of transcription in response to growth factors.
Conversely, it is likely that the inability of myocardin to activate the c-fos promoter is due, at least in part, to the binding of Elk-1 to the serum response element of the c-fos promoter. Consistent with this idea, they showed that deletion of the Elk-1 binding site within the c-fos promoter conferred partial sensitivity of the c-fos promoter to myocardin (106) . Of interest, these studies showed that Elk-1 suppressed the activity of smooth muscle-restricted promoters, including the telokin promoter that does not contain a consensus Elk-1 binding site, through its ability to block myocardin-induced activation of the promoters (107). investigation of their role in SMC phenotypic switching following vascular injury or in experimental atherosclerosis will be dependent on development of conditional knockout and/or chimeric knockout mice, since conventional knockout of each of these genes is associated with early embryonic or prenatal lethality (4, 44, 60, 84, 88, 89) . In addition, there is a critical need to: 1) identify humoral factors that mediate SMC phenotypic switching other than PDGF-BB and in particular to investigate the role of inflammatory cytokines and other pro-atherogenic factors found within diseased blood vessels; 2) elucidate specific molecular mechanisms and factors that confer responsiveness of SMC in intact blood vessels to humoral factors like PDGF-BB which can clearly induce profound changes in gene expression patterns in cultured SMC but which appear to be incapable by themselves of doing this in fully differentiated SMC in vivo; 3) more fully characterize the nature of changes in gene expression that characterize SMC phenotypic switching in different disease states including examination of genes that play a functional role in the disease pathophysiology; and 4) better understand differences and similarities in regulation of SMC phenotypic switching between diverse SMC subtypes, including coronary arteries, the outflow tract, large conduit arteries in the body trunk, and peripheral arteries which have diverse embryological origins (26), as well as functional properties (87) .
Finally, the so called synthetic state SMC presumably evolved as a highly regulated state of the SMC for purpose of vascular injury repair -a process that is undoubtedly critical for survival and hence these mechanisms have been conserved across very diverse species and hundreds of millions of years of evolution. In contrast, virtually all diseases in which SMC phenotypic switching plays a key role, including atherosclerosis, have their negative survival consequences beyond the reproductive period such that there presumably has been little or no evolutionary selection pressure against these changes. As such, although SMC phenotypic switching in disease may share some common regulatory mechanisms and mediators with those that occur with vascular injury/repair, there may also be key differences that are critical to the pathobiology of SMC related diseases. It is also important to emphasize the importance of temporal changes in the nature and consequences of SMC phenotypic Myocardin-related transcription factor B is required in cardiac neural crest for smooth muscle 
